VivoSeq
Cardiovascular

Myocardial Protection

0

Pipeline Programs

1

Active Trials

0

Companies Involved

Myocardial Protection is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

6/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed10 · 63%
Unknown status4 · 25%
Recruiting1 · 6%
Terminated1 · 6%

Trial Activity

16 trials

Pediatric Myocardial Protection With Potassium Cardioplegia
Completed··Phase 2·NCT03229980·87 enrolled
Myocardial Protection and Anesthetic Agents
Completed··Phase 4·NCT02405689·60 enrolled
Levosimendan and Myocardial Protection
Completed·UUniversity of Roma La Sapienza·Phase 4·NCT00610350·100 enrolled
Remote Preconditioning and Myocardial Protection
Completed··Phase 2·NCT02877238·91 enrolled
Myocardial Protection With Adenosine Preconditioning
Completed·XXijing Hospital·Phase 1/2·NCT00881686·238 enrolled
Desflurane-induced Myocardial Protection
Unknown status··Phase 4·NCT02019797·50 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)